<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873065</url>
  </required_header>
  <id_info>
    <org_study_id>LivzonIY-81149R-11-02</org_study_id>
    <nct_id>NCT02873065</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Livzon Pharmaceutical Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Livzon Pharmaceutical Group Inc.</source>
  <brief_summary>
    <textblock>
      This study compared efficacy and safety of Ilaprazole based triple regimen therapy including&#xD;
      Ilaprazole 5mg, Clarithromycin 500mg and Amoxicillin Cap(Amoxicillin) 1000mg BID on the first&#xD;
      line eradication treatment of H.pylori&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants are defined as persons who have endoscopically confirmed on gastric or duodenal&#xD;
      ulcer(including scar stage) ,gastritis and dyspepsia confirmed to be H.pylori positive&#xD;
      patients in the biopsy and UBT test. For 7 days, Participants treated as Esoprazole based&#xD;
      triple regimen therapy therapy including Esoprazole 20mg，Clarithromycin 500mg and Amoxicillin&#xD;
      Cap(Amoxicillin) 1000mg BID. After treatment, The healing rate was evaluated in the UBT test&#xD;
      and Biopsy at 49±5days from the first day dosing&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date>June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate of Helicobacter pylori as assessed by UBT test</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of side effects of each treatment</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Helicobacter Pylori Eradication</condition>
  <arm_group>
    <arm_group_label>Ilaprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ilaprazole -based quadruple therapy for 7days：Ilaprazole -based quadruple therapy for 7days: Ilaprazole 5mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esoprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ilaprazole</intervention_name>
    <arm_group_label>Ilaprazole</arm_group_label>
    <other_name>Ilaprazole and amoxicillin 1000mg bid, clarithromycin 500mg bid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esoprazole</intervention_name>
    <arm_group_label>Esoprazole</arm_group_label>
    <other_name>Esoprazole and Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must have endoscopically confirmed on gastric, duodenal ulcer(including scar)&#xD;
             or gastritis confirmed to be H.pylori positive patients in the biopsy and UBT test.&#xD;
&#xD;
          -  Subject who fully understands conditions of clinical trial.&#xD;
&#xD;
          -  Subject who agrees to participate and spontaneously sign the ICF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to any component of ilaprazole, Esoprazole, Amoxicillin and&#xD;
             Clarithromycin&#xD;
&#xD;
          -  Subjects who are taking contraindicated medications for experimental and concomitant&#xD;
             drug&#xD;
&#xD;
          -  Administrated of PPI, antibiotic medication within 4 weeks prior to commencement of&#xD;
             the study&#xD;
&#xD;
          -  Pregnant and/or lactating women&#xD;
&#xD;
          -  Reproductive aged women not using contraception&#xD;
&#xD;
          -  Uncontrolled diabetics&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Uncontrolled liver dysfunction&#xD;
&#xD;
          -  Alcoholics&#xD;
&#xD;
          -  Subjects with a history of digestive malignancy within 5 years&#xD;
&#xD;
          -  Subjects with a history of gastrectomy or esophagectomy&#xD;
&#xD;
          -  Subjects with hereditary diseases such as Galactose intolerance, Lapp lactose&#xD;
             deficiency, glucose-galactose malabsorption&#xD;
&#xD;
          -  Subjects participating in a clinical trial before another trial within 30 days&#xD;
&#xD;
          -  Inconsistent judged subject by researcher&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>August 16, 2016</last_update_submitted>
  <last_update_submitted_qc>August 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

